Figure 2.

(a, b) Cumulative incidence of virologic failure among children and adolescents on second-line treatment. (a) Primary analysis and (b) secondary analysis.

Virologic failure in the primary analysis is defined as two consecutive VL results >1000 copies/ml after at least six months of second-line treatment (n = 722) and in the secondary analysis as a single VL >1000 copies/ml after at least six months of second-line treatment (n = 911). T0 is set at six months after treatment switch; total follow-up time is 60 months.